Track topics on Twitter Track topics that are important to you
Christian Jorgensen, chief executive of Biotec Pharmacon (FRA:B4V), talks Proactive London's Andrew Scott through the firm's two technology platforms - one of them's a unique enzymes platform where they sell to diagnostics and gene therapy companies.
The second platform is focused on BetaGlucens which develops and manufactures immune modulating compounds for the human health sectors. The technology's currently being used in a wound care product called Woulgan.NEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...